Qiming Venture Leads $21M Series A Round In Chinese Biopharma Firm Antengene

Jillian Yue
August 16, 2017 — 08:15 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: Antengene biotech China chinese healthcare HG Capital Hong Kong investment manufacturing qiming Qiming Venture Partners singapore South Korea taiwan Thailand venture capital zhejiang

Related News:

Saudi Arabia’s FoFs Jada Backs eWTP Arabia Capital’s Second Fund

December 9, 2023 — 02:30

Chinese Charitable Foundations Expand Into Alternative Investments To Enhance Returns

November 30, 2023 — 23:50

Bahrain’s Investcorp Targets RMB2-4 Billion Buyout Fund in China

November 25, 2023 — 00:58

Chinese Generative AI Startups Secure Substantial Funding in Race to Replicate OpenAI’s Success

November 13, 2023 — 23:55

Middle Eastern Sovereign Wealth Funds Deepen Investment in China

November 10, 2023 — 23:35

Reports Indicate NVIDIA Tailoring Specialized Chips for China’s Market

November 9, 2023 — 23:26

Kai-Fu Lee’s AI Firm 01.AI Hits Unicorn Status with Alibaba Cloud-Led Funding

November 7, 2023 — 00:55

AI-Driven Pharmaceutical Startups Attract Soaring Investor Interest

November 5, 2023 — 03:24

ByteDance Invested In 52 Deals With Total Deal Value Of $6.4B: TikTok Parent Company’s Investments, M&A, Strategic Deals In One Chart 2019-2022

April 29, 2022 — 01:44

Franchising and Licensing Asia (FLAsia) 2024